



Experiences with Symbiosis LC-MS/MS Bioanalysis in the lower pg/mL region in serum and whole blood

Dr. Claudia Hartig
Pharmacokinetics/Bioanalysis

Schering AG, D-13342 Berlin claudia.hartig@schering.de +49 30 468 12845

Agenda

- Bioanalysis at Schering AG
- Example 1
- Example 2
- Summary

Bioanalysis at Schering AG

Group within Preclinical development/Pharmacokinetics

Bioanalysis for preclinical and clinical studies

Formulation analysis for preclinical studies

4 scientists, 14 technicians

Bioanalysis: quantification and metabolite identification

Quantification:

2x API365, 2x API3000, 1x API4000, 1x API4000QTrap,
1x ELAN9000

Metabolite ID:

1x API3, 1x QToF Ultima Global, 1x LCQ duo,
1x LTQ FT MS

Bioanalysis at Schering AG - quantification

7.75 FTEs dedicated to quantitative bioanalysis

MD/MV per year (per species, matrix) 30 - 50

sample throughput per year 20000

issue: sensitivity versus timelines

LLOQs < 100 pg/mL

MD/MV per project 3 months

low degree of automatisation, experiences before Symbiosis

- λ Tecan Genesis for SPE
- λ Packard Multiprobe for LLE
- λ Spark Prospect for SPE in metabolism studies
- λ TFC in metabolism studies

Example 1 - introduction

compound characteristics

- λ ca. 500 u
- λ nonpolar (log P_{OW} 4.6)
- λ insoluble in water at pH 7 and pH 3.7
- λ pK_a 1.65

development for oral application (dermatology)


- λ highly potent - low dosage, low LLOQ (10 pg/mL) in serum
- λ online design of phase I dose escalation study

experience with Tox species (LLOQ 30 pg/mL)

- λ problems with chemical interference and matrix effects in serum and plasma
- λ solved with extensive LC and atmospheric pressure photo-ionisation (APPI) detection
- λ laborious and time consuming but robust method

Example 1 - manual work-up

SPE



HPLC





A: water B: ACN

step	time hh:mm:ss	A [%]	B [%]	Flow [mL/min]
1	00:00:00	70	30	0.2
2	00:08:00	30	70	0.2
3	00:08:10	0	100	0.2
4	00:12:00	0	100	0.2
5	00:12:10	70	30	0.2
6	00:17:00	70	30	0.2

Detection

+ve APPI API3000

Example 1 - manual work-up, chromatograms



sufficient sensitivity, no carry-over

Example 1 - manual work-up vs. Symbiosis

SPE Phenyl Strata
100 mg/1 mL

HySphere Resin GP
10-12µm

1 mL MeOH
2 mL H₂O

conditioning

solvation
equilibration

1 mL MeOH
1 mL H₂O

300 µL sample
500 µL ISTD
vortex mix

sample loading

sample loading

250µL
partial loopfill

350 µL sample
30 µL ISTD
vortex mix

2 mL MeOH/H₂O 50:50
1 mL MeOH/H₂O 50:50,
2% CH₃COH

wash

sample extraction

1 mL H₂O

wash

2 mL H₂O

1 mL MeOH

elution

elution

0.2 mL ACN

drying

30 µL ACN/H₂O 70:30



re-dissolve

inject 5 µL

injection

step	time hh:mm:ss	A [%]	B [%]	Flow [mL/min]	
1	00:00:01	100	0	0.2	focussing
2	00:02:00	100	0	0.2	focussing
3	00:02:01	70	30	0.2	
4	00:05:00	30	70	0.2	
5	00:06:00	0	100	0.2	
6	00:09:00	0	100	0.2	
7	00:09:01	70	30	0.2	
8	00:12:01	100	0	0.2	

Example 1 - Symbiosis work-up, overall sensitivity




2.3 pg on column

Comparison with manual work-up:



0.5 pg on column

ca. 5 times more sensitive

Note: modified LC method had no influence





Example 1 - Symbiosis work-up, carry-over



Carry over [%]

1.1



0.7

Example 1 - intermediate results

Method does not reach desired sensitivity

method optimisation with regard to
extraction efficiency
matrix interference

Method has unacceptable carry-over

carry-over is linear throughout concentration range:


STD conc [ng/mL]	area	solvent blank area	carry-over [%]
1	66538	564	0.8
2.5	146314	1355	0.9
7.5	418459	4239	1.0
10	474286	4176	0.9

reduction of calibrated range to e.g. 0.01 - 1 ng/mL not possible

further method optimisation and wash programs...

Example 1 - method optimisation

HySphere C18 HD
7µm



Autosampler program
SparkLink 3.9

Line	Wash Vol	SSV port
1	700 µL	2
2	700 µL	3
3	700 µL	2

2 MeOH/H2O 10:90
3 MeOH/0.1% HCO2H 50:50

clamp flush
0.5 mL H₂O




wash cartridge
3 mL ACN/H₂O 90:10

clamp flush
0.5 mL ACN/H₂O 90:10
0.5 mL H₂O

step	time hh:mm:ss	A [%]	B [%]	Flow [mL/min]	
1	00:00:01	90	10	0.2	focussing
2	00:02:00	90	10	0.2	focussing

Example 1 - successful elimination of carry-over

- 1 Wait for Input 2-LOW
- 2 Valve ISS-A 1-2
- 3 Wait for Input 3-LOW
- 4 Syringe Valve SOLVENT 3
- 5 Wait 00:00:06
- 6 Valve INJ Load
- 7 Wash 500 µl
- 8 Valve INJ Inject
- 9 Wash 500 µl
- 10 Valve INJ Load
- 11 Wash 500 µl
- 12 Valve INJ Inject
- 13 Wash 500 µl
- 14 Syringe Valve SOLVENT 2
- 15 Valve INJ Load
- 16 Wash 500 µl
- 17 Valve INJ Inject
- 18 Wash 500 µl
- 19 Valve INJ Load
- 20 Wash 500 µl
- 21 Valve INJ Inject
- 22 Wash 500 µl
- 23 Syringe Valve SOLVENT 3
- 24 Valve INJ Load
- 25 Wash 2500 µl
- 26 Valve INJ Inject
- 27 Aspirate 90 µl From: Sample Speed: 3 Height: 5
- 28 Valve INJ Load Sync
- 29 Aspirate 250 µl From: Sample Speed: 3 Height: 5
- 30 Valve INJ Inject Sync
- 31 Marker INJECT
- 32 Dispense 340 µL To: Waste Speed: 6 Height: 0
- 33 Syringe HOME
- 34 Syringe Valve SOLVENT 3
- 35 Syringe LOAD 250 µl Speed: 6
- 36 Syringe Valve NEEDLE
- 37 Dispense 250 µl To: Waste Speed: 6 Height: 0
- 38 Syringe Valve SOLVENT 3
- 39 Wash 1000 µl
- 40 End



But no improvement of sensitivity

Example 2 - introduction

Compound characteristics

- λ ca. 450 u
- λ polar ($\log P_{OW}$ 1.29 at pH 7, determined by HPLC)
- λ insoluble in water at pH 7, slightly soluble at pH 1.1 and in organic solvents
- λ pK_a 4.0, 10.3

development for oral application (oncology)

- λ whole blood analysis (+ plasma and urine)
- λ Phase I concentration range approx. 100 pg/mL - 1 µg/mL

experience with Tox species (LLOQ 5 ng/mL)

- λ problems with sticky behaviour and sample matrix
- λ solved with extensive sample preparation and +ve ESI detection
- λ laborious and time consuming but robust method

Example 2 - development of two methods

Split of concentration range:

5.0 ng/mL - 1.0 µg/mL

0.1 ng/mL - 10 ng/mL

development of method for the high concentration range in analogy to manual work-up method



Example 2 - sample preparations, LLOQ 5 ng/mL

manual

SPE Oasis HLB
1cc (30mg)

HySphere Resin GP
10-12µm

Symbiosis



API365

API4000

time hh:mm:ss	A [%]	B [%]	Flow [mL/min]
00:00:01	75	25	0.3
00:01:00	75	25	0.3
00:05:00	25	75	0.3
00:05:20	0	100	0.5
00:06:00	0	100	0.5
00:06:20	75	25	0.5
00:09:00	75	25	0.3

time hh:mm:ss	A [%]	B [%]	Flow [mL/min]
00:00:01	90	10	0.35
00:02:00	90	10	0.35
00:02:05	75	25	0.30
00:03:00	75	25	0.30
00:07:00	25	75	0.30
00:07:12	0	100	0.50
00:09:00	0	100	0.50
00:11:00	90	10	0.35

Example 2 - Symbiosis wash programs

HySphere Resin GP
10-12µm

solvation
equilibration 1 mL MeOH
1 mL 5% MeOH

sample loading 50µL partial loopfill vortex mix centrifuge
50 µL sample
50 µL ISTD
1900 µL buffer

sample extraction 0.5 mL 5% MeOH

wash 1 mL 5% MeOH
1 mL MeOH/2% NH₄OH 40:60
1 mL 5% MeOH
1 mL MeOH/2% CH₃CO₂H 40:60
1 mL 5% MeOH

elution 0.2 mL MeOH/H₂O 70:30

injection

Autosampler program
SparkLink 3.10

valve wash
2 mL MeOH


clamp flush
0.5 mL MeOH/H₂O 70:30
0.5 mL H₂O
0.5 mL MeOH/H₂O 70:30

Line	Wash Vol	SSV port	Valve wash
1	1000 µL	1	No
2	1000 µL	2	No
3	1000 µL	1	No
4	1000 µL	1	Yes
5	1000 µL	2	Yes
6	1000 µL	3	Yes
7	1000 µL	1	Yes
8	1000 µL	1	Yes
9	1000 µL	1	Yes

1 5% MeOH
2 MeOH
3 MeOH/2% CH₃CO₂H 40:60

Example 2 - comparison of LLOQ 5 ng/mL methods


Manual work-up: carry-over 0.09%; area LLOQ/ area blank 11.2




Example 2 - method adjustment for LLOQ 100 pg/mL

method 100 pg/mL - 10 ng/mL

method 5 ng/mL - 1 µg/mL



Example 2 - results for LLOQ 100 pg/mL method



Summary

- easy method adjustment for lower LLOQ
- carry-over concentration dependent?

Further considerations and summary

Method transfer time:

from March to September 2004 (2 people, not full-time)

In the beginning we needed support from Spark (for the autosampler program) - this was granted generously.

With the first Symbiosis Pharma system we initially had some problems with the system performance. However, after an upgrade program from Spark these performance problems were solved.

Apart from that:

The system is suited for our purpose (low LLOQs, low carry-over), but low LLOQs need more than average method development capacities
SparkLink 3.10 helped a lot in reducing carry-over, remaining substance may derive from the LC connection (T-piece for focussing mode)

Thanks

Spark Holland: everybody who helped, especially Martin Sibum



The group

